Terri Imada, APRN
Adult Health · Honolulu, HINPI 1568672038
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Myriad Women's Health, Inc. accounts for 61.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $2,752 and has fallen 88.9% since, to $305 in 2025.
Across 70 payments — averaging $55.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Women's Health, Inc.$2K
- Novartis$277
- Johnson & Johnson$262
- Merck$243
- Incyte Corporation$117
- AstraZeneca$112
- plus $491 from 12 others
What the payments were for
- Speaking & faculty fees$1,95050%
- Travel & lodging$3369%
- Food & beverage$1,57741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Women's Health, Inc. | 8 | $2,359 |
| Novartis | 13 | $277 |
| Johnson & Johnson | 10 | $262 |
| Merck | 11 | $243 |
| Incyte Corporation | 3 | $117 |
| AstraZeneca | 6 | $112 |
| Myriad Genetic Laboratories, Inc. | 2 | $111 |
| Genentech USA, Inc. | 3 | $75 |
| Seagen Inc. | 2 | $58 |
| Ipsen Biopharmaceuticals, Inc | 3 | $57 |
| Bayer | 2 | $39 |
| Tersera Therapeutics LLC | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Genmab U.S., Inc. | 1 | $25 |
| Springworks Therapeutics, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myRisk$2,173
How this compares
$3,863 in reported general payments places this provider in the 85th percentile of 44 adult health providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Raloxifene Hcl | 61 | $8,314 |
| Anastrozole | 13 | $929 |
Paid to pharmacies, not to this prescriber.
Other adult health in Honolulu
- Christina WangHonolulu$257K
- Christella GuzmanHonolulu$8K
- Hee Yun JangHonolulu$6K
- Harold Marion PalmaHonolulu$4K
- Mandi BentonHonolulu$4K
- Lauren ThomasHonolulu$4K
- Reid KawakamiHonolulu$3K
- Carl PitreHonolulu$2K
- Chen Yen WangHonolulu$2K
- Rozanne SchirmerHonolulu$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.